Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | CETP | P11597 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21278650 | 0.91 | GPR119 (0.41) | GPR119MAPK14KCNH2MCHR1LIMK2 | |
| SCHEMBL17986551 | 0.88 | LIMK2 (0.33) | GPR119LIMK2CETP | |
| SCHEMBL18017459 | 0.88 | GPR119 (0.31) | GPR119LIMK2CETP | |
| SCHEMBL16629857 | 0.87 | CETP (0.36) | GPR119LIMK2CETP | |
| SCHEMBL18017460 | 0.87 | CETP (0.34) | GPR119LIMK2CETP | |
| SCHEMBL16619381 | 0.87 | CETP (0.36) | GPR119LIMK2CETP | |
| SCHEMBL17986542 | 0.87 | GPR119 (0.39) | GPR119LIMK2CETP | |
| SCHEMBL17986544 | 0.87 | GPR119 (0.39) | GPR119LIMK2CETP | |
| SCHEMBL16620144 | 0.87 | GPR119 (0.39) | GPR119LIMK2CETP | |
| SCHEMBL17986536 | 0.87 | CETP (0.35) | GPR119LIMK2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486448-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486448-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235727-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | GPR119 138/4885MAPK14 4047/4885KCNH2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.